RESEARCH TRIANGLE PARK, NC (February 27, 2023) – Dignify Therapeutics LLC, a pharmaceutical and medical device development company focused on restoring bladder and bowel control for people with spinal injury, multiple sclerosis, diabetes, and the elderly, was awarded the prestigious Blueprint Neurotherapeutics Network grant from the National Institutes of Health (NIH). This 4-year award provides over $4 million in funding to support preclinical and clinical development of the Company’s lead drug candidate, DTI-117, to treat bladder and bowel dysfunction.
“This new award exemplifies the foresight of, and commitment from, the NIH to develop treatments for bladder and bowel dysfunction in people suffering from these conditions” said company President and Principal Investigator, Dr. Ed Burgard. “This award will provide funds for an IND submission and a subsequent clinical trial for DTI-117”.
Dignify is developing novel drug and device therapies for bladder and bowel dysfunction to eliminate or reduce the need for life-long, multiple-daily catheterization of the bladder and difficult and time-consuming manual bowel programs. Worldwide bladder catheter sales total $3 billion/year, while health care expenditures associated with voiding dysfunction cost $7 billion/year in the US alone. Success of Dignify’s development programs will not only improve the quality of life for individuals with voiding dysfunction but will also reduce health care costs.
About Dignify Therapeutics LLC
Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, treatments for bladder and bowel voiding dysfunctions, primarily using a repositioning strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology. The Company is funded through venture capital (RA Capital Mgmt and Eshelman Ventures), angel investors, the NIH, the North Carolina Biotechnology Center and the One NC Small Business Program. Dignify Therapeutics is located at the First Flight Venture Center in Research Triangle Park, North Carolina.
This content is solely the responsibility of Dignify Therapeutics and does not necessarily represent the official views of the NIH.
PRESS CONTACT
Dignify Therapeutics
Ed Burgard
P.O. Box 13169
2 Davis Drive
Research Triangle Park, NC 27709
Phone: 919-371-8138
Email: eburgard@dignifytherapeutics.com
